Table 1.
Baseline characteristics of the study population.
|
PD patients (n = 1,385) |
Patients with WO (n = 763) | Patients without WO (n = 622) | p | |
|---|---|---|---|---|
| Male, n (%)a,$ | 737 (53.2%) | 410 (53.7%) | 327 (52.6%) | 0.67 |
| Age (years)b,& | 69.7 (9.5) | 70.1 (9.75) | 69.1 (9.1) | 0.05 |
| Age at onset (years)b,& | 64.0 (10.0) | 63.2 (10.04) | 65.0 (9.4) | 0.001* |
| Weight (kg)b,& | 62.2 (10.0) | 61.7 (10.03) | 62.8 (9.8) | 0.035* |
| Disease duration (years)b,& | 5.8 (4.7) | 7.0 (4.8) | 4.2 (4.1) | <0.001* |
| H&Yb,& | 2 (1.0) | 2.5 (1.0) | 2.0 (1.0) | <0.001* |
| LD (mg/day)b,& | 396.3 (242.7) | 442.5 (248.9) | 339.6 (222.3) | <0.001* |
| LED (mg/day)b,& | 487.7 (272.7) | 546.8 (280.9) | 415.1 (243.5) | <0.001* |
| Duration of anti-parkinsonian medical treatment (years)b,& | 3.9 (3.7) | 4.8 (4.0) | 2.89 (3.4) | <0.001* |
| Duration of levodopa treatment (years)b,& | 3.7 (3.9) | 4.5 (4.15) | 2.7 (3.4) | <0.001* |
WO, Wearing-off; H&Y, Hoehn & Yahr; LD, levodopa dose; LED, levodopa equivalent dose.
a
Presented as number (percentage).
b
Presented as mean (standard deviation).
$
Data were analyzed by χ2 test.
&
Data were analyzed by Mann–Whitney U test.
*
p < 0.05 of the comparison between two groups.